Abstract
Currently, special attention is paid to timely treatment for active forms of multiple sclerosis (MS), especially for highly active MS (HAMS), in which there are ≥2 exacerbations and corresponding activity signs that are detected by magnetic resonance imaging (MRI) regardless of previous therapy with MS-modifying drugs (MSMDs) or there is ≥1 exacerbation and corresponding activity signs revealed by MRI during therapy with other MSMDs. A group of expert neurologists from various clinics in Russia, who actively participate in the clinical trials of cladribine tablets in MS, presents a consensus on the practical aspects of using the tablets of cladribine registered in Russia in March 2020 for the treatment of patients with HAMS. The paper mentions the groups of patients in whom the drug, an examination before starting a therapy cycle, routes of administration, and dose, and a monitoring scheme during and after treatment cycles are indicated. This drug acts on the principle of selective immunoreconstitution and may occupy an important place in the treatment of HAMS.
Highlights
«Ростовский государственный медицинский университет» Минздрава России, Ростов-на-Дону; 7ГБУ МО «Научнопрактический центр клинико-экономического анализа» Минздрава Московской области, Красногорск; 8ФГБНУ «Научный центр неврологии», Москва; 9ГБУЗ НО «Государственная Новосибирская областная клиническая больница», Областной центр рассеянного склероза, Новосибирск; 10ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России, Новосибирск; 11ГБУЗ «Самарская областная клиническая больница им
Special attention is paid to timely treatment for active forms of multiple sclerosis (MS), especially for highly active MS (HAMS), in which there are ≥2 exacerbations and corresponding activity signs that are detected by magnetic resonance imaging (MRI) regardless of previous therapy with MS-modifying drugs (MSMDs) or there is ≥1 exacerbation and corresponding activity signs revealed by MRI during therapy with other MSMDs
A group of expert neurologists from various clinics in Russia, who actively participate in the clinical trials of cladribine tablets in MS, presents a consensus on the practical aspects of using the tablets of cladribine registered in Russia in March 2020 for the treatment of patients with HAMS
Summary
«Ростовский государственный медицинский университет» Минздрава России, Ростов-на-Дону; 7ГБУ МО «Научнопрактический центр клинико-экономического анализа» Минздрава Московской области, Красногорск; 8ФГБНУ «Научный центр неврологии», Москва; 9ГБУЗ НО «Государственная Новосибирская областная клиническая больница», Областной центр рассеянного склероза, Новосибирск; 10ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России, Новосибирск; 11ГБУЗ «Самарская областная клиническая больница им. Которым наиболее показан препарат, обследование перед началом курса терапии, способ применения и дозы, схема мониторинга во время и после курсов лечения. Рекомендации по использованию кладрибина в таблетках для патогенетического лечения пациентов с высокоактивным рассеянным склерозом.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
